Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Articles

These articles are provided free to all readers.  Other free articles are available in Week in Review, In My Opinion, and Education Center.  To have access to all of our articles, click here...

Week in Review: Ocumension Climbs to $2.5 Billion Market Cap after $184 Million Hong Kong IPO

Sinovac Approved to Start Phase III Trial of COVID-19 Vaccine in Brazil

Week in Review: China Life Science Announces Deals Worth $1.3 Billion

Week in Review: VistaGen Out-Licenses China/Asia Rights for Novel Anxiety Drug to EverInsight in $177 Million Deal

VistaGen Signs $177 Million Deal with EverInsight for China/Asia Rights to VistaGen's Anxiety Drug

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China